Let’s Keep the Door to Biotechnological Eugenics Closed
By Enola Aird,
MomsRising
| 02. 10. 2014
Remember the
three-parent babies I told you about in December? The ones made with genetic material from two different women? Well, the United States might be moving a step closer to their creation.
A Food and Drug Administration (FDA) Advisory Committee will hold a
public meeting on February 25 and 26 regarding clinical trials of mitochondrial transfer procedures (MT). I’ve submitted a written
statement and received FDA permission to present my arguments at the meeting. I’ll be there to oppose the use of such procedures because they would permanently change the genes passed down to future generations.
A quick reminder of what’s at stake. The Advisory Committee will consider whether to allow human clinical trials of “oocyte modification in assisted reproduction for the prevention of the transmission of mitochondrial disease or treatment of infertility.” That’s a long way of referring to a form of genetic modification that would alter an embryo’s genetic structure in such a way that the changes would be passed down to all future generations of the same line.
To accomplish this sci-fi sounding task, scientists would...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...